ARCA's Bucindolol Clinical Trial Plan Gets FDA Green Light; Firm Evaluates Funding Options

The FDA has approved a trial investigating bucindolol in approximately 3,200 chronic heart failure patients who have a genotype associated with response to the beta-blocker and mild vasodilator.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.